0%

NuvaPineA®

Antioxidant

Bioeffective® A was trialled at the St. Petersburg State Scientific Research Institute of Cardiology at the Russian Ministry of Health, in patients with ischemic heart disease with disorders of lipid metabolism. Treatment with Bioeffective® A helped normalise markers of lipid metabolism and reduce the rate of lipid peroxidation in 70.3% of patients. The study showed that Bioeffective® A is beneficial for patients with cardiovascular diseases. (Shevchenko I.A. et al., 2000)

Anti-microbial

Therapeutic efficacy was studied in 94 children, aged four and above, predisposed to illness (more than 4 times per year), with chronic bronchopulmonary disorders. Patients were hospitalised at the St. Olga Municipal Paediatric Hospital with diagnosis of Acute Viral Respiratory Infections (ARVI).

Test Substance Duration of symptoms, days
BOS Rhinitis Fever Coughing Auscultatory changes Acute phase of disease Frequency of intrahospital infections
Bioeffective® A (n=42) 4.4+0.6 5.7+0.4* 3.7+0.3* 8.4+0.6* 6.9+0.6* 9.7+0.5* 16.7*
Placebo (n=52) 5.1+0.4 12.9+0.4 4.9+0.3 18.8+0.3 10.3+0.4 15.9+0.6 25.8

BOS – Bronchial obstructive syndrome; IHI – intrahospital infection; n = number of children; *-p<0.05 in comparison to the placebo group.

Conclusion: Inclusion of Bioeffective® A as adjuvant to primary therapy facilitated quicker recovery from Acute Respiratory Disease (ARD), including those with chronic recurring diseases of the respiratory system. (Osidak L.V et al.Paediatric Infections, 2006, No.2, pp.47-51).

Prophylactic efficacy was studied in 264 children at two St. Petersburg paediatric facilities and at the health centre for TB-infected children.

Patients Medication Number of children Number of children contracting disease Number of complications EI EEC
abs. % (%)
TB-infected children Bioeffective® A 66 5 5.3 0** 3.3 69.7
Placebo 57 12 17.5 50

Efficacy index; EEC – epidemic efficacy coefficient, ** – significant difference in comparison to not prone to infection children.

Conclusion: Bioeffective® A was shown to be able to protect against TB infections.

Gastrointestinal Healing

Bioeffective® A was administered to patients with atrophic gastritis and compared to a control group. Patients in the Bioeffective® A–treated group experienced a 92% improvement in dyspeptic symptoms (GERD) such as gastritis, acid reflux, gas and bowel disorders, a 58% improvement in stomach functionality, a 46% reduction in pre-cancerous lesions and a 57% H.pylori eradication rate. (Vladimir G. Bespalov, Vagif S. Soultanov et al. Pre-cancerous Conditions and Changes of the Stomach and their Correction. Medline-Express No. 2-3 (202), 2009).

Detoxification

Kazan Republican Infectious Diseases Hospital trialled Bioeffective® A as an adjuvant in the treatment of patients with chronic hepatitis. Bioeffective® A addition lead to the faster restoration of liver function, diminishment of anaemia symptoms and a reduction in the severity of side effects caused by interferon therapy (Bulatova N.A., 2000).